NEW YORK (GenomeWeb News) – MDxHealth today announced the creation of a new division focused on expanding its companion diagnostics capabilities.
The new division, called MDxHealth PharmacoDx, will be based in Ghent, Belgium, and will collaborate with the University of Ghent to leverage next-generation epigenetic sequencing technology in order to "enhance" MDxHealth's offerings and designs of companion diagnostics and other tests for use in the development of new drugs and treatments for cancer, it said in a statement.
MDxHealth also plans to integrate its Flemish subsidiary with its new PharmacoDx facility.
The Liege, Belgium-based firm, which recently announced a change in its business strategy, has already been collaborating with the University of Ghent in bioinformatics and translational medicine.
In a statement, Jan Groen, CEO of MDxHealth, said that building out the company's relationship with the university "is key for our pharmaco-diagnostic development capabilities. The development and commercialization of clinical and companion diagnostics are at the heart of MDxHealth's growth strategy."